@carisls profile picture
Caris Life Sciences @carisls

Caris Life Sciences, the precision medicine pioneer, develops and delivers innovative solutions to revolutionize healthcare and improve the human condition.

Joined March 2011
  • Tweets 7,271
  • Following 2,895
  • Followers 22,623
2,343 Photos and videos
Fragmented genetic testing can limit insight into myeloid malignancies. Caris ChromoSeq consolidates multiple methods into one Whole Genome Sequencing (WGS) assay, delivering a comprehensive view to support diagnosis and risk stratification. Learn more: bit.ly/4ufznZw
1
4
348
MI Cancer Seek® offers an innovative approach to cancer care. As the first simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) FDA-approved CDx for solid tumors, it provides comprehensive insights for adult and pediatric patients, helping clinicians make more informed treatment decisions. Discover more and view important product information: bit.ly/4lyGNTR
0:30
1
4
7
582
During Men’s Health Month, we recognize the impact of cancer on men across the U.S. At Caris, comprehensive molecular profiling helps support informed treatment decisions by bringing clarity to complex cancer biology. Learn more: bit.ly/4gOuelO
1
156
Advancing precision oncology starts with better data. Caris Life Sciences provides that with Caris Assure®. Caris Assure sequences whole blood, analyzing plasma alongside matched white blood cells to help distinguish tumor-derived alterations from clonal hematopoiesis (CH) and incidental germline findings. Discover how this assay drives confidence and clarity: bit.ly/4eYqHQO
1
1
191
Join the interactive Caris symposium during the UK Oncology Forum (UKOF) to explore how comprehensive molecular profiling, tissue and liquid sequencing, and AI insights are being applied to optimize therapeutic approaches. Learn more: ow.ly/JnzQ50Z7LLp
1
2
183
June is National Cancer Survivor Month. According to the American Association for Cancer Research (@AACR), more than 18 million people in the U.S. are living with a history of cancer, each with a survivorship journey shaped by individual care and support needs. Hear from patients who have shared their perspectives and experiences with Caris, offering personal cancer journey insights that far transcend data: bit.ly/49Bo2uV
1
1
363
Caris Life Sciences announced that its Board of Directors has authorized a share repurchase program for up to $100 million of the Company’s outstanding common stock. Learn more: ow.ly/EvYm50Z8gyM
1
5
4
768
Clarity at diagnosis means increased confidence in treatment decisions. Caris MI Clarity™ delivers independent recurrence risk across two critical time horizons in early-stage breast cancer. Physicians, take a closer look at the data behind MI Clarity and gain early access: ow.ly/9FsJ50Z7NWl
2
4
257
When advancing cancer care requires clarity, precision matters. Join Caris Life Sciences at the UK Oncology Forum 2026 to explore how comprehensive molecular profiling supports more informed decision-making across oncology. Visit us at Stand G38 to connect with our team and discuss real-world applications in personalized medicine. Connect with Caris: ow.ly/b0re50Z7LKi
4
234
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric patients (ages 1 ). Learn more: bit.ly/4lyGNTR
4
3
287
Emily Alouani, MD presented findings demonstrating how large-scale genomic profiling can identify new immunotherapy-sensitive cancer subsets. Her analysis revealed that MSH3 loss-of-function (LOF) alterations define a subset of tumors with enhanced sensitivity to immune checkpoint blockade beyond MSI status. These results supported MSH3 LOF as a potential predictive biomarker for immunotherapy benefit and highlighted the value of large-scale clinico-genomic analyses in biomarker discovery. #ASCO26
2
3
297
Join the conversation with Caris Chief Medical Officer George Sledge Jr., MD, during the AI in Action: Real-World Healthcare AI Deployments webinar. In his session “From Discovery to Delivery: How AI Is Reshaping Biotech,” learn how AI in life sciences is evolving, helping improve research and clinical workflows and shaping the future of healthcare. Register here: ow.ly/4q9e50Z6iNb
3
1
310
Our team is waiting to chat with you at booth 27059. Take advantage of the opportunity to network with Caris during #ASCO26. bit.ly/4ecyVWB
1
194
Caris Chief Medical Officer, George Sledge, Jr., MD will present findings from a study of nearly 28,000 breast tumors showing ESR1 amplification is a rare subtype associated with reduced overall survival and shorter time on palbociclib. #ASCO26
2
3
375
Connect with Caris at #ASCO26! Meet with our team, hear the latest information on our current product offerings and learn about the most advanced approach to precision medicine. Visit booth 27059. bit.ly/4ecyVWB
1
2
2
318
Myeloid malignancies are genetically complex and often require multiple assays. Caris ChromoSeq brings the full genomic landscape into one high-coverage Whole Genome Sequencing (WGS) test, supporting clearer diagnosis and risk stratification in a single report. Learn more during #ASCO26: bit.ly/4ecyVWB
2
3
242
Caris’ strong presence at #ASCO26 demonstrates the clinical value of comprehensive molecular profiling and our commitment to transforming lives through research. Discover more about our groundbreaking studies. bit.ly/4ecyVWB
1
2
4
226
How can new immunotherapy-sensitive cancer subsets be identified? Attend Emily Alouani, MD’s Rapid Oral presentation during #ASCO26 to hear how large-scale genomic profiling showed that MSH3 loss-of-function alterations define a subset of tumors with enhanced sensitivity to immune checkpoint blockade beyond MSI status.
1
4
202
The American Society of Clinical Oncology (@ASCO) Annual Meeting is underway. Stop by Booth 27059 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. Come have coffee on us! bit.ly/4ecyVWB #ASCO26
1
5
291
Load more